Search Result

Results for "

99mtc

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Biochemical Assay Reagents (2) Bombesin Receptor (1) Drug Derivative (1) EGFR (1) FAP (3) Isotope-Labeled Compounds (1) PD-1/PD-L1 (1) Prostaglandin Receptor (1) PSMA (5) Radionuclide-Drug Conjugates (RDCs) (6) Somatostatin Receptor (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148152A

PSMA I&S TFA	PSMA	Others
PSMA I&S (TFA) is a precursor of the 99mTc-labeled PSMA-targeting ligand .

HY-P10369

Betiatide	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Inflammation/Immunology
Betiatide, as a chelating agent for Technetium-99m ( ^99mTc), is used to prepare ^99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-47979A

FAP-IN-2 TFA	FAP	Others Cancer
FAP-IN-2 TFA is a ^99mTc-labeled isonitrile-containing FAP inhibitor derivative that can be used for tumor imaging .

HY-47979

FAP-IN-2	FAP	Others Cancer
FAP-IN-2 is a derivative of ^99mTc-labeled isonitrile-containing fibroblast activation protein (FAPI) inhibitor, that can be used for tumor imaging .

HY-148152

PSMA I&S	PSMA	Others
PSMA I&S is a precursor of the 99mTc-labeled PSMA-targeting ligand .

HY-P10846

HYNIC-CTP	Isotope-Labeled Compounds	Cardiovascular Disease
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide ^99mTc through HYNIC acting as a chelator, forming ^99mTc-HYNIC-CTP. ^99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .

HY-114133

Depreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-124192

Amogastrin	Prostaglandin Receptor	Cancer
Amogastrin is a tetrapeptide that stimulates gastric extraction of ^99mTc pertechnetate. Amogastrin can be used for the research of gastric mucosal disease imaging. Amogastrin stimulates the production of prostate hormones .

HY-145769

N2S2-CBMBC	PD-1/PD-L1	Cancer
N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use ^99mTc-labelled complexes ^99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method .

HY-122939

MAIPGG	Radionuclide-Drug Conjugates (RDCs)	Cancer
MAIPGG is a bifunctional chelator and an intermediate in the synthesis of radionuclide drug conjugates (RDCs). MAIPGG can be for the radiolabeling of a variety of monoclonal antibodies with ^99mTc or ¹⁸⁶Re, which then can be used for radioimmunodetection and radioimmunotherapy of cancer .

HY-172366

BQ0413	PSMA	Cancer
BQ0413 exhibits good affinity to PSMA with a K_D of 89 pM. BQ0413 exhibits good uptake and internalization property with an internalization rate of 44% in PC3-pip cell. BQ0413 can be used as tumor imaging agent when labeled with 99mTc .

HY-155470

IMP 243	Biochemical Assay Reagents	Cancer
IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with ^99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41. HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-163545

Tc-Me2P	Drug Derivative	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-D2281

FAP Ligand 2	FAP	Cancer
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

Cat. No.	Product Name	Type

HY-D2281

FAP Ligand 2	Dyes
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

Cat. No.	Product Name	Target	Research Area

HY-P10369

Betiatide	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Inflammation/Immunology
Betiatide, as a chelating agent for Technetium-99m ( ^99mTc), is used to prepare ^99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10846

HYNIC-CTP	Isotope-Labeled Compounds	Cardiovascular Disease
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide ^99mTc through HYNIC acting as a chelator, forming ^99mTc-HYNIC-CTP. ^99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .

HY-114133

Depreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41. HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.